Zhejiang Starry Pharmaceutical Co.,Ltd. (SHA:603520)
China · Delayed Price · Currency is CNY 13.93
+0.80 (6.09%)
May 20, 2026, 1:35 PM CST
SHA:603520 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2,471 | 2,446 | 2,013 | 1,996 | 1,868 | 1,873 |
Other Revenue | - | - | 337.09 | 200.4 | 263.61 | 126.7 |
| 2,471 | 2,446 | 2,350 | 2,196 | 2,131 | 2,000 | |
Revenue Growth (YoY) | 3.23% | 4.06% | 7.02% | 3.04% | 6.57% | 46.29% |
Cost of Revenue | 1,932 | 1,942 | 1,920 | 1,688 | 1,629 | 1,255 |
Gross Profit | 539.47 | 503.59 | 430.39 | 507.69 | 502.59 | 744.81 |
Selling, General & Admin | 260.27 | 251.24 | 244.51 | 227 | 216.31 | 150.57 |
Research & Development | 137.36 | 128.22 | 140.67 | 134.56 | 132.61 | 124.58 |
Other Operating Expenses | -12.51 | -12.93 | -15.69 | 5.17 | 14.39 | 15.44 |
Operating Expenses | 385.11 | 366.54 | 367.62 | 356.13 | 363.45 | 303.69 |
Operating Income | 154.35 | 137.06 | 62.77 | 151.57 | 139.14 | 441.12 |
Interest Expense | - | - | -96.16 | -102.6 | -92.6 | -73.82 |
Interest & Investment Income | - | - | 8.41 | 7.55 | 20.63 | 12.93 |
Currency Exchange Gain (Loss) | - | - | -10.57 | 4.61 | -26.98 | -1.39 |
Other Non Operating Income (Expenses) | -88.46 | -83.21 | -7.46 | -7.76 | -11.09 | 1.36 |
EBT Excluding Unusual Items | 66.27 | 53.85 | -43.02 | 53.36 | 29.1 | 380.2 |
Impairment of Goodwill | - | - | - | - | -114.75 | - |
Gain (Loss) on Sale of Investments | -9.43 | -9.12 | -9.61 | -14.1 | 0.88 | 0.16 |
Gain (Loss) on Sale of Assets | 0.36 | 0.45 | -4.01 | 3.03 | -3.39 | -4.02 |
Asset Writedown | -38.82 | -38.19 | -9.71 | -3.84 | - | - |
Other Unusual Items | - | - | 8.94 | 6.89 | 22.75 | 19.06 |
Pretax Income | 18.38 | 7 | -57.17 | 45.35 | -65.4 | 395.39 |
Income Tax Expense | 1.55 | -3.28 | -8.07 | 0.8 | 6.53 | 65.62 |
Earnings From Continuing Operations | 16.82 | 10.27 | -49.1 | 44.55 | -71.93 | 329.77 |
Minority Interest in Earnings | 0.01 | -0.05 | 0 | -0.32 | -3.92 | -6.01 |
Net Income | 16.84 | 10.23 | -49.1 | 44.23 | -75.85 | 323.75 |
Net Income to Common | 16.84 | 10.23 | -49.1 | 44.23 | -75.85 | 323.75 |
Net Income Growth | - | - | - | - | - | 35.62% |
Shares Outstanding (Basic) | 497 | 511 | 409 | 340 | 345 | 344 |
Shares Outstanding (Diluted) | 497 | 511 | 409 | 340 | 345 | 344 |
Shares Change (YoY) | 9.90% | 24.99% | 20.25% | -1.31% | 0.10% | 3.05% |
EPS (Basic) | 0.03 | 0.02 | -0.12 | 0.13 | -0.22 | 0.94 |
EPS (Diluted) | 0.03 | 0.02 | -0.12 | 0.13 | -0.22 | 0.94 |
EPS Growth | - | - | - | - | - | 31.60% |
Free Cash Flow | -399.28 | -265.53 | -287.12 | -221.67 | -550.56 | 204.96 |
Free Cash Flow Per Share | -0.80 | -0.52 | -0.70 | -0.65 | -1.60 | 0.59 |
Dividend Per Share | - | - | 0.150 | - | 0.500 | 0.357 |
Dividend Growth | - | - | - | - | 40.02% | - |
Gross Margin | 21.83% | 20.59% | 18.31% | 23.12% | 23.58% | 37.24% |
Operating Margin | 6.25% | 5.60% | 2.67% | 6.90% | 6.53% | 22.06% |
Profit Margin | 0.68% | 0.42% | -2.09% | 2.01% | -3.56% | 16.19% |
Free Cash Flow Margin | -16.16% | -10.86% | -12.22% | -10.09% | -25.83% | 10.25% |
EBITDA | 399.78 | 377.18 | 281.65 | 331.12 | 297.97 | 594.55 |
EBITDA Margin | 16.18% | 15.42% | 11.98% | 15.08% | 13.98% | 29.73% |
D&A For EBITDA | 245.42 | 240.12 | 218.89 | 179.55 | 158.83 | 153.43 |
EBIT | 154.35 | 137.06 | 62.77 | 151.57 | 139.14 | 441.12 |
EBIT Margin | 6.25% | 5.60% | 2.67% | 6.90% | 6.53% | 22.06% |
Effective Tax Rate | 8.44% | - | - | 1.76% | - | 16.60% |
Revenue as Reported | - | - | 2,350 | 2,196 | 2,131 | 2,000 |
Advertising Expenses | - | - | 111.83 | 85.39 | 60.3 | 8.8 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.